GCP
CDTX

GSA Capital Partners’s Cidara Therapeutics CDTX Stock Holding History

GSA Capital Partners’s Portfolio CDTX Stock Details CDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-22,830
Closed -$420K – 1662
2024
Q1 		$420K Sell
22,830
-4,192
-16% -$60.2K 0.03% 999
2023
Q4 		$429K Buy
27,022
+20,173
+295% +$324K 0.04% 894
2023
Q3 		$129K Buy
+6,849
New +$134K 0.01% 1364
2021
Q2 		– Sell
-8,937
Closed -$475K – 1338
2021
Q1 		$475K Sell
8,937
-39
-0.4% -$1.93K 0.08% 384
2020
Q4 		$359K Buy
8,976
+7,684
+595% +$382K 0.06% 639
2020
Q3 		$74K Buy
+1,292
New +$91.3K 0.01% 1160

Other funds holding CDTX

MIM
Monashee Investment Management Boston, Massachusetts $59.6M AUM 181.61% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Checkpoint Capital San Francisco, California $390M AUM 96.52% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
ACM
Alethea Capital Management Mercer Island, Washington $241M AUM 112.74% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return

GSA Capital Partners's CDTX Position: Q2 2024 in Review

GSA Capital Partners sold out of Cidara Therapeutics (CDTX) in Q2 2024, closing a stake of 22,830 shares — an estimated $420K sold.

GSA Capital Partners first reported a position in CDTX in Q3 2020 and held it in 6 quarters. The position peaked at $475K in Q1 2021. 26 funds tracked by Wall St. Rank hold CDTX as of Q2 2024.

  • GSA Capital Partners reported no remaining Cidara Therapeutics position as of Q2 2024 after selling out during the quarter.
  • GSA Capital Partners sold 22,830 Cidara Therapeutics shares in Q2 2024, an estimated $420K.
  • GSA Capital Partners first reported a position in Cidara Therapeutics in Q3 2020 and held it in 6 quarters.
  • GSA Capital Partners's Cidara Therapeutics position peaked at $475K in Q1 2021.
  • 26 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q2 2024.

Based on GSA Capital Partners's 13F filing for Q2 2024, filed 15 Aug 2024.